

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

Date Submitted: September 27, 2010

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/784,900
Filing Date	2/24/2004
First Named Inventor	Eugene R. Cooper
Art Unit	1615
Examiner Name	Tran, Susan T.
Attorney Docket Number	029318-1003



Sheet 1 of 7

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	2003/0119825 A1	6/26/2003	Folger et al.	
	A2	2010/0137292 A1	6/3/2010	Turp et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1	WO 2005/105101 A1	11/10/2005	Friton et al.		
	B2	WO 2006/000306 A1	1/5/2006	Friton et al.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C1	Ahmed et al., "Meloxicam in rheumatoid arthritis," pp. 739-751 (2005).	
	C2	Altman et al., "Efficacy Assessment of Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary Syndromes without ST-Segment Elevation," 191-195 (2002).	
	C3	Aoki et al., "Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery," pp. 613-617 (2006).	
	C4	Auvinet et al., "Comparison of the Onset and Intensity of Action of Intramuscular Meloxicam Oral Meloxicam in Patients with Acute Sciatica," <i>Clin. Therap.</i> , Vol. 17, No. 6, pp. 1078-1090 (1995).	
	C5	Barner, "Review of Clinical Trials and Benefit/Risk Ratio of Meloxicam," pp. 29-37 (1996).	
	C6	Bosch et al., "Efficacy and Tolerability of Intramuscular and Oral Meloxicam in Patients with Acute Lumbago: A Comparison with Intramuscular and Oral Piroxicam," pp. 29-38 (1997).	
	C7	Busch et al., "Pharmacokinetics of Meloxicam in Animals and the Relevance to Humans," <i>Drug Metabolism and Disposition</i> , Vol. 26, No. 6, pp. 576-584 (1998).	

Examiner Signature

/Susan Tran/

Date Considered

11/02/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<b>Application Number</b>	10/784,900	
Date Submitted: September 27, 2010			<b>Filing Date</b>	2/24/2004	
(use as many sheets as necessary)			<b>First Named Inventor</b>	Eugene R. Cooper	
			<b>Art Unit</b>	1615	
			<b>Examiner Name</b>	Tran, Susan T.	
			<b>Attorney Docket Number</b>	029318-1003	
Sheet	2	of	7		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C8	Busch et al., "The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man," pp. 269-272 (1995).	
	C9	Calvo et al., "Analgesic and anti-inflammatory dose-response relationship of 7.5 and 15 mg meloxicam after lower third molar removal: a double-blind, randomized, crossover study," <i>Int. J. Oral Maxillofac. Surg.</i> , Vol. 36, pp. 26-31 (2007).	
	C10	Chen et al., "Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation," <i>Vol. 12, No. 11, 4 pgs.</i> (2008).	
	C11	Chung, "The Use of Injectable Nonsteroidal Anti-Inflammatory Drugs in Local Accident & Emergency Practice," <i>Hong Kong Journ. of Emerg. Med.</i> , pp. 65-71 (2002).	
	C12	Colberg et al., "The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago," <i>Current Medical Research and Opin.</i> , Vol. 13, No. 7, pp. 363-377 (1996).	
	C13	Combe et al., "Comparison of Intramuscular and Oral Meloxicam in Rheumatoid Arthritis Patients," pp. 10-16 (2001).	
	C14	Davies et al., "Clinical Pharmacokinetics of Meloxicam," pp. 115-126 (1999).	
	C15	DeAndrade et al., "Ketorolac Versus Meperidine for Pain Relief After Orthopaedic Surgery," pp. 302-312 (1996).	
	C16	Degner et al., "Pharmacological, Pharmacokinetic and Clinical Profile of Meloxicam," <i>Drugs of Today</i> , Vol. 33, No. 10, pp. 739-758 (1997).	
	C17	Del Tacca et al., "Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug," <i>Clin. Drug. Invest.</i> , Vol. 22, No. 12, pp. 799-818 (2002).	
	C18	Engelhardt, "Meloxicam Inhibits Preferentially COX-2," <i>Euro. Journ. of Pharm.</i> , Abstracts of 4 <sup>th</sup> Annual Meeting of the German Society of Clin. Pharmacology and Therapy, 2 pgs. (1994).	
	C19	Engelhardt et al., "Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance," <i>Inflamm. Res.</i> , Vol. 44, pp. 423-433 (1995).	
	C20	Euller-Ziegler et al., "Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration," pp. 5-9 (2001).	

Examiner Signature	/Susan Tran/	Date Considered	11/02/2010
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/784,900
Date Submitted: September 27, 2010		<b>Filing Date</b>	2/24/2004
(use as many sheets as necessary)		<b>First Named Inventor</b>	Eugene R. Cooper
		<b>Art Unit</b>	1615
		<b>Examiner Name</b>	Tran, Susan T.
		<b>Attorney Docket Number</b>	029318-1003
Sheet	3	of	7

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C21	Filatova et al., "Efficacy of movalis in the treatment of acute low back pains," pp. 33-37 (2005). [ENGLISH ABSTRACT]	
	C22	Furst, "Meloxicam: Selective COX-2 Inhibition in Clinical Practice," pp. 21-27 (1997).	
	C23	Gates et al., "Meloxicam: a reappraisal of Pharmacokinetics, efficacy and safety," pp. 2117-2140 (2005).	
	C24	Gebuhr et al., "A Multiple-dose, Double-blind Comparison of Intramuscularly and Orally Administered Ketorolac Tromethamine and Ketogan® in Patients with Pain Following Orthopaedic Surgery," pp. 202-217 (1994).	
	C25	Ghazian et al., "Tolerability of Multiple Administration of Intramuscular Meloxicam: A comparison with Intramuscular Piroxicam in patients with rheumatoid arthritis or osteoarthritis," pp. 51-55 (1996).	
	C26	Gillis et al., "Ketorolac: A Reappraisal of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Pain Management," <i>Drugs</i> , Vol. 53, No. 1, pp. 139-188 (1997).	
	C27	Haas et al., "An Update on Analgesics for the Management of Acute Postoperative Dental Pain," <i>Journ. of the Canadian Dental Assoc.</i> , Vol. 68, No. 8, pp. 476-482 (2002).	
	C28	Hawkey et al., "Gastrointestinal Tolerability of Meloxicam Compared to Diclofenac in Osteoarthritis Patients," <i>British Society for Rheumatology</i> , pp. 937-945 (1998).	
	C29	Hill et al., "Analgesic Efficacy of the Cyclooxygenase-Inhibiting Nitric Oxide Donor AZD3582 in Postoperative Dental Pain: Comparison with Naproxen and Rofecoxib in Two Randomized, Double-Blind, Placebo-Controlled Studies," <i>Clinical Therapeutics</i> , Vol. 28, No. 9, pp. 1279-1295 (2006).	
	C30	Hinz et al., "Can Drug Removals Involving Cyclooxygenase-2 Inhibitors be Avoided? A Plea for Human Pharmacology," <i>Trends in Pharmacological Sciences</i> , pp. 391-397 (2008).	
	C31	Hosein et al., "Evaluation of Meloxicam (A Cox-2 Inhibitor) for Management of Postoperative Endodontic Pain: A Double-blind Placebo-controlled Study," <i>Journ. of Endodontics</i> , pp. 634-637 (2003).	
	C32	Issioui et al., "The Efficacy of Premedication with Celecoxib and Acetaminophen in Preventing Pain After Otolaryngologic Surgery," <i>Anesh. Analog.</i> , pp. 1188-1193 (2002).	
	C33	Jick, "The Risk of Gastrointestinal Bleed, Myocardial Infarction and Newly Diagnosed Hypertension in Users of Meloxicam, Diclofenac, Naproxen, and Piroxicam," <i>Pharmacotherapy</i> , Vol. 20, No. 7, pp. 741-744 (2000).	

Examiner Signature	/Susan Tran/	Date Considered	11/02/2010
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/784,900
<b>Date Submitted: September 27, 2010</b>		<b>Filing Date</b>	2/24/2004
<b>(use as many sheets as necessary)</b>		<b>First Named Inventor</b>	Eugene R. Cooper
		<b>Art Unit</b>	1615
		<b>Examiner Name</b>	Tran, Susan T.
		<b>Attorney Docket Number</b>	029318-1003
<b>Sheet</b>	4	<b>of</b>	7

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C34	Kurukahvecioglu et al., "Effect of Meloxicam on Postoperative Pain Relief after Inguinal Hernia Repair with Local Anaesthesia," <i>West Indian Med. J.</i> , Vol. 56, No. 6, pp. 530-533 (2007).	
	C35	Lugar et al., "Structure and physicochemical properties of meloxicam, a new NSAID, pp. 175-187 (1996).	
	C36	Malan et al., "The Cyclooxygenase-2 Specific Inhibitor Parecoxib Sodium is as Effective as 12 mg of Morphine Administered Intramuscularly for Treating Pain After Gynecologic Laparotomy Surgery," <i>Anesth Analg.</i> , pp. 454-460 (2005).	
	C37	Mazurov et al., "Use of meloxicam (movalis) in patients with rheumatic diseases with concomitant coronary heart disease," <i>Klin Med (Mosk)</i> , Vol. 82, No. 12, pp. 54-59 (2004). [English Abstract]	
	C38	Mitchell et al., "Clinico-pharmacological studies on Ketoprofen ('Orudis'), pp. 423-430 (1975).	
	C39	Naidu et al., "Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems," pp. 75-86 (2004).	
	C40	Narjes et al., "Pharmacokinetics and tolerability of meloxicam after i.m. administration," <i>Br. J. Clin. Pharm.</i> , Vol. 41, pp. 135-139 (1996).	
	C41	Narjes et al., "Parenteral Tolerability of Meloxicam in Healthy Volunteers," page 61 [P07]. no date	
	C42	Nekoofar et al., "Evaluation of Meloxicam (A COX-2 Inhibitor) for Management of Postoperative Endodontic Pain: A Double-blind Placebo-controlled Study," <i>Journ. of Endodontics</i> , Vol. 29, No. 10, pp. 634-637 (2003).	
	C43	Nikanne et al., "Comparison of perioperative ketoprofen 2.0 mg kg <sup>-1</sup> with 0.5 mg kg <sup>-1</sup> i.v. in small children during adenoidectomy," <i>British Journ. of Anaesthesia</i> , Vol. 79, pp. 606-608 (1997).	
	C44	Odinak et al., "Use of Movalis in Treatment of Dorsopathy," 29-32 (2004). [ENGLISH ABSTRACT INCLUDED]	
	C45	Palangio et al., "Combination Hydrocodone and Ibuprofen Versus Combination Oxycodone and Acetaminophen in the Treatment of Postoperative Obstetric or Gynecologic Pain," <i>Clin. Therapeutics</i> , Vol. 22, No. 5, pp. 600-612 (2000).	
	C46	Pallapies et al., "Effects on Platelet Functions and Pharmacokinetics of Azapropazone and Ketorolac Tromethamine Given as Single Parenteral Doses," pp. 335-339 (1993).	

<b>Examiner Signature</b>	/Susan Tran/	<b>Date Considered</b>	11/02/2010
---------------------------	--------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/784,900
Date Submitted: September 27, 2010		<b>Filing Date</b>	2/24/2004
(use as many sheets as necessary)		<b>First Named Inventor</b>	Eugene R. Cooper
		<b>Art Unit</b>	1615
		<b>Examiner Name</b>	Tran, Susan T.
		<b>Attorney Docket Number</b>	029318-1003
Sheet	5	of	7

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C47	Panara et al., "Dose-Dependent Inhibition of Platelet Cyclooxygenase-1 and Monocyte Cyclooxygenase-2 by Meloxicam in Healthy Subjects, pp. 276-280 (1999).	
	C48	Power et al., "Comparison of I.M. Ketorolac Trometamol and Morphine Sulphate for Pain Relief after Cholecystectomy," <i>British Journ. of Anaesthesia</i> , Vol. 65, pp. 448-455 (1990).	
	C49	Rani et al., "Determination of Oral Meloxicam Pharmacokinetic Parameters in Asian Indians: Comparison with a German Population," <i>Saudi Pharm. J.</i> , Vol. 12, No. 4, pp. 144-149 (2004).	
	C50	Rao et al., "Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond," <i>J. Pharm. Pharmacol. Sci.</i> , pp. 81-110 (2008).	
	C51	Rinder et al., "Effects of Meloxicam on Platelet Function in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial," <i>J. Clin. Pharmacol.</i> , Vol. 42, pp. 881-886 (2002).	
	C52	Romsing et al., "Postoperative Analgesia is not Different After Local vs Systemic administration of Meloxicam in Patients Undergoing Inguinal Hernia Repair," <i>Can. J. Anesth.</i> , Vol. 48, No. 10, pp. 978-984 (2001).	
	C53	Schmid et al., "Pharmacokinetics and Metabolic Pattern after Intravenous Infusion and Oral Administration to Healthy Subjects," pp. 1206-1213 (1995).	
	C54	Singh et al., "Risk of Serious Upper Gastrointestinal and Cardiovascular Thromboembolic Complications with Meloxicam," pp. 100-106 (2004).	
	C55	Stei et al., "Local Tissue Tolerability of Meloxicam, A New NSAID: Indications for Parenteral, Dermal and Mucosal Administration," <i>British Journ. of Rheumatology</i> , Vol. 35 (Suppl. 1), pp. 44-50 (1996).	
	C56	Strand, "Are COX-2 Inhibitors Preferable to Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Patients with Risk of Cardiovascular Events Taking Low-Dose Aspirin?," <i>Lancet</i> , pp. 2138-2151 (2007).	
	C57	Sunshine et al., "Analgesic Efficacy of a Hydrocodone with Ibuprofen Combination Compared with Ibuprofen Alone for the Treatment of Acute Postoperative Pain," <i>J. Clin. Pharmacol.</i> , Vol. 37, pp. 908-915 (1997).	
	C58	Swamy et al., "Oral Dispersible Tablets of Meloxicam using Disintegrant Blends for Improved Efficacy," <i>Indian Journ. of Pharm. Sci.</i> , pp. 836-841 (2007).	
	C59	Thompson et al., "Effect of Meloxicam on Postoperative Pain After Abdominal Hysterectomy," <i>British Journ. of Anaesth.</i> , Vol. 84, No. 2, pp. 151-154 (2000).	

Examiner Signature	/Susan Tran/	Date Considered	11/02/2010
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/784,900
Date Submitted: September 27, 2010		<b>Filing Date</b>	2/24/2004
(use as many sheets as necessary)		<b>First Named Inventor</b>	Eugene R. Cooper
		<b>Art Unit</b>	1615
		<b>Examiner Name</b>	Tran, Susan T.
		<b>Attorney Docket Number</b>	029318-1003
Sheet	6	of	7

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C60	Thwaites et al., "Intravenous Ketorolac Tromethamine Does not Worsen Platelet Function During Knee Arthroscopy Under General Anesthesia," <i>Anesth. Analg.</i> , Vol. 81, pp. 119-124 (1995).	
	C61	Thwaites et al., "Intravenous Ketorolac Tromethamine Worsens Platelet Function During Knee Arthroscopy Under Spinal Anesthesia," <i>Anesth. Analg.</i> , Vol. 82, pp. 1176-1181 (1996).	
	C62	Turck et al., "Clinical Pharmacokinetics of Meloxicam," <i>Arzneim.-Forsch./Drug Res.</i> , Vol. 47(I), pp. 253-258 (1997).	
	C63	Van Hecken et al., "Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers," <i>J. Clin. Pharm.</i> , Vol. 40, pp. 1109-1120 (2000).	
	C64	Van Kraaij et al., "A comparison of the effects of nabumetone vs. meloxicam on serum thromboxane B <sub>2</sub> and platelet function in healthy volunteers," pp. 644-647 (2002).	
	C65	Weber et al., "COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam," pp. 963-966 (2003).	
	C66	Wideman et al., "Analgesic Efficacy of a combination of hydrocodone with ibuprofen in postoperative pain," pp. 66-76 (1999).	
	C67	Zelenak et al., "Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain," <i>J. Clin. Pract.</i> , Vol. 58, No. 3, pp. 251-256 (2004).	
	C68	Gravestock, Analytical Service Report, Meloxicam pKa and Solubility Analysis, 7 pgs., (2008).	
	C69	Gravestock, Meloxicam Aq GI-Dissolution, 3 pgs. (2008).	
	C70	Dreiser et al., "Oral meloxicam is effective in acute sciatica: two randomised, double-blind trials versus placebo or diclofenac," <i>Inflamm Res.</i> , Vol. 50, Suppl 1, pp. S17-23 (2001).	
	C71	Akarsu et al., "Preemptive meloxicam for postoperative pain relief after abdominal hysterectomy," <i>Clin Exp Obstet Gynecol.</i> , Vol. 31, No. 2, pp. 133-136 (2004).	
	C72	De Mello et al., "Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea," <i>Acta Obstet Gynecol Scand.</i> , Vol. 83, No. 7, pp. 667-73 (2004).	

Examiner Signature	/Susan Tran/	Date Considered	11/02/2010
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/784,900
<b>Date Submitted: September 27, 2010</b>		<b>Filing Date</b>	2/24/2004
<b>(use as many sheets as necessary)</b>		<b>First Named Inventor</b>	Eugene R. Cooper
		<b>Art Unit</b>	1615
		<b>Examiner Name</b>	Tran, Susan T.
		<b>Attorney Docket Number</b>	029318-1003
<b>Sheet</b>	7 of 7		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C73	Cheng et al., "A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis," <i>Clin Ther.</i> , Vol. 26, No. 3, pp. 399-406 (2004).	
	C74	Carroll et al., "Analgesic efficacy of preoperative administration of meloxicam or butorphanol in onychectomized cats," <i>J. Am. Vet. Med. Assoc.</i> , Vol. 226, No. 6, pp. 913-9 (2005).	
	C75	Deneuche et al., "Analgesic comparison of meloxicam or ketoprofen for orthopedic surgery in dogs," <i>Vet Surg.</i> , Vol. 33, No. 6, pp. 650-660 (2004).	
	C76	Fowler et al., "An evaluation of the analgesic effects of meloxicam in addition to epidural morphine/mepivacaine in dogs undergoing cranial cruciate ligament repair," <i>Can. Vet. J.</i> , Vol. 44, No. 8, pp. 643-8 (2003).	
	C77	Caulkett et al., "A comparison of the analgesic effects of butorphanol with those of meloxicam after elective ovariohysterectomy in dogs," <i>Can. Vet. J.</i> , Vol. 44, No. 7, pp. 565-70 (2003).	
	C78	Budberg et al., "Evaluation of intravenous administration of meloxicam for perioperative pain management following stifle joint surgery in dogs," <i>Am J Vet Res.</i> , Vol. 63, No. 11, pp. 1557-63 (2002).	
	C79	Lascelles et al., "Evaluation of the clinical efficacy of meloxicam in cats with painful locomotor disorders," <i>J. Small Anim Pract.</i> , Vol. 42, No. 12, pp. 587-93 (2001).	
	C80	Mathews et al., "Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery," <i>Am J Vet Res.</i> , Vol. 62, No. 6, pp. 882-8 (2001).	
	C81	Scientific Discussion, EMEA, 1-96 (2007).	

<b>Examiner Signature</b>	/Susan Tran/	<b>Date Considered</b>	11/02/2010
---------------------------	--------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.